achieve adequate expansion can lead to severe aortic regurgitation that could have a negative influence on the postoperative course. We propose that, when the prostheses is seen to have an asymmetric morphology during the procedure, the echocardiographic examination should include measurement of the major diameter. If it is greater than the nominal diameter and there is central regurgitation, regardless of the severity, the balloon should be reinflated and, if this proves to be ineffective, a “valve-in-valve” procedure should even be considered to increase the radial strength. In any case, close observation with serial echocardiograms will be necessary to enable the early detection of functional deterioration in the prostheses and the need for therapeutic intervention.

Miguel A. Cavero, a, * Javier Goicoe, b Carlos García-Montero, c and Juan F. Oteo d

aUnidad de Imagen Cardiaca, Servicio de Cardiología, Hospital Puerta de Hierro, Majadahonda, Madrid, Spain
bUnidad de Cardiología Intervencionista, Servicio de Cardiología, Hospital Puerta de Hierro, Majadahonda, Madrid, Spain
cServicio de Cirugía Cardiaca, Hospital Puerta de Hierro, Majadahonda, Madrid, Spain

d* Corresponding author:
E-mail address: mcvero.hpht@salud.madrid.org (M.A. Cavero).

Available online 23 July 2011

REFERENCES


Impact of Adjunctive Cilostazol Therapy Versus High Maintenance Dose of Clopidogrel in Suboptimal Responders With Diabetes Mellitus

Impacto del tratamiento adyuvante con cilostazol comparado con dosis altas de mantenimiento de clopidogrel en pacientes con diabetes mellitus y respuesta subóptima

To the Editor,

Patients with type 2 diabetes mellitus type 2 (T2DM) have a high prevalence of poor response to clopidogrel, which may contribute to their increased risk of recurrent atherothrombotic events.1 These findings underscore the need to optimize platelet inhibition in these patients.2 The OPTIMUS (Optimizing Antiplatelet Therapy in Diabetes Mellitus)-1 and -2 studies observed that a high clopidogrel maintenance dose regimen (150 mg/day)3 and adjunctive cilostazol therapy (100 mg twice daily),4 respectively, were associated with greater platelet P2Y12 inhibition compared with standard clopidogrel therapy (75 mg/day) in T2DM patients. However, it is unknown which of these is more effective in inhibiting P2Y12 signaling in T2DM patients with suboptimal response to standard dosing. The aim of this investigation was to compare the magnitude of P2Y12 inhibitory effects of high maintenance dose clopidogrel and adjunctive cilostazol therapy among T2DM patients with stable coronary artery disease presenting with suboptimal clopidogrel response.

This analysis includes subjects with suboptimal clopidogrel response, while on dual therapy with acetylsalicylic acid and clopidogrel 75 mg daily for at least 30 days, randomized in the OPTIMUS-1 and -2 trials. Details of the inclusion/exclusion criteria for the trials have previously been published.3,4 For the purpose of this analysis, patients from both studies with suboptimal response defined according to their P2Y12 reactivity index (PRI), the most specific marker of P2Y12 mediated signalling, were analyzed. PRI values were obtained with flow cytometric analysis of the status of phosphorylation of the vasodilator-stimulated phosphoprotein according to standard protocols.3,4 A cut-off value of PRI >50% was considered to define suboptimal responders, which reflects a consensus definition as this has been associated with an increased risk of atherothrombotic events.1,2

Statistical comparison of PRI continuous values was conducted using a general linear model with treatment as a fixed effect, subject as a random effect, and baseline PRI value as a covariate. Results are reported as least squares mean ± standard error of the mean. Chi-square test or Fisher’s exact test (according to application conditions) was used to compare the percentage of clopidogrel responders between treatments (dichotomic variable).

A total of 30 patients with suboptimal clopidogrel response treated with either adjunctive cilostazol therapy (n = 15) or high maintenance dose clopidogrel (n = 15) were identified. There were no differences in baseline characteristics between groups (data not shown). PRI values prior to treatment assignment were also similar (67.5 ± 2.1 vs 70.6 ± 2.8; P = .404).

Both treatments were effective in reducing PRI (P < .001 for both). However, patients treated with cilostazol had lower PRI compared with 150 mg clopidogrel (45.1 ± 3.1 vs 54.8 ± 3.1; P = .037; Fig. 1A). The absolute change in PRI was 24.0 ± 3.1 in clopidogrel and 14.2 ± 3.1 for the high maintenance dose clopidogrel (P = .037), leading to an absolute 9.7% (confidence interval 95%: 0.7%-18.9%) greater decrease in PRI with cilostazol (Fig. 1B). Accordingly, the prevalence of suboptimal responders was also significantly lower using clostazol (20% vs 66.7%; P = .010; Fig. 1C).

The present investigation shows that among T2DM patients with poor response to standard dual antiplatelet therapy (DAPT), the adjunctive use of cilostazol (also known as “triple therapy”) is associated with a greater magnitude of P2Y12 inhibitory effects compared with high maintenance dose clopidogrel. Importantly, levels of platelet reactivity and the prevalence of suboptimal responders are markedly lower with triple therapy. This may explain why adjunctive cilostazol therapy is more effective than DAPT in reducing atherothrombotic events, particularly in patients with DM.2 On the contrary, high maintenance dose clopidogrel is still associated with a high prevalence of poor responders, which may also explain
why this strategy has failed to ameliorate outcomes. Our results are in line with those obtained in an unselected cohort of patients.

Indeed, strategies using novel P2Y12 receptor antagonists, such as prasugrel, enhance platelet inhibition in patients with DM. These may also explain the pronounced benefit of prasugrel in DM patients. However, prasugrel is associated with increased bleeding, which does not occur with adjunctive cilostazol therapy. Notably, many DM patients also have a history of a prior cerebrovascular event, a contraindication for prasugrel use, whereas cilostazol has shown to be safe and efficacious.

We acknowledge the inherent limitations of this investigation as being a post-hoc retrospective analysis. Indeed, a prospective randomized study is warranted to confirm our findings. In addition, the clinical implications of such treatment remain elusive, underscoring the need for further investigations to test its safety and efficacy.

José L. Ferreiro,a,b Masafumi Ueno, Bhaloo Desai, Piera Capranzano,a Davide Capodanno,a and Dominick J. Angiolilloa,*

aUniversity of Florida College of Medicine, Jacksonville, Florida, United States
bLaboratorio de Investigación Cardiovascular, Área de Enfermedades del Corazón, Hospital Universitari de Bellvitge, IDIBELL, Universidade de Barcelona, L’Hospitalet de Llobregat, Barcelona, Spain

*Corresponding author:
E-mail address: dominick.angiolillo@jax.ufl.edu (D. J. Angiolillo).
Available online 23 July 2011

REFERENCES


doi:10.1016/j.rec.2011.04.007